JAMES BRUCE BUSSEL

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint Novel approaches to refractory immune thrombocytopenic purpura
    J B Bussel
    Department of Pediatrics, Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood Rev 16:31-6. 2002
  2. ncbi request reprint AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
    James B Bussel
    New York Presbyterian Hospital, New York, USA
    N Engl J Med 355:1672-81. 2006
  3. ncbi request reprint Novel thrombopoietic agents: preliminary activity, potential benefit
    James B Bussel
    Weill Cornell Medical College, Division of Pediatric Hematology, Payson 609, 525 E 68th Street, New York, NY 10021, USA
    J Support Oncol 5:63-84. 2007
  4. ncbi request reprint Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates
    James B Bussel
    Division of Hematology, Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021 4853, United States
    Blood Rev 22:33-52. 2008
  5. pmc Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration
    James B Bussel
    Departments of Pediatrics and Medicine, Division of Hematology Oncology, Weill Cornell Medical College, New York, NY, USA
    Haematologica 99:1264-71. 2014
  6. ncbi request reprint Thrombopoietic agents: There is still much to learn
    James B Bussel
    Weill Cornell Medical College, Platelet Disorders Center, Departments of Pediatrics and Medicine, Division of Hematology, New York, NY 10065, United States Electronic address
    Presse Med 43:e69-78. 2014
  7. doi request reprint Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)
    James B Bussel
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Br J Haematol 160:538-46. 2013
  8. pmc Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective
    Susan D Mathias
    Health Outcomes Solutions, P, O, Box 2343 Winter Park, Florida 32790, USA
    Health Qual Life Outcomes 6:13. 2008
  9. pmc A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation
    Susan D Mathias
    Ovation Research Group, 188 Embarcadero, San Francisco, CA 94105, USA
    Health Qual Life Outcomes 5:11. 2007
  10. ncbi request reprint Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
    James B Bussel
    Weill Cornell Medical College of Cornell University, New York, NY 10065, USA
    N Engl J Med 357:2237-47. 2007

Research Grants

  1. Novel Therapies in Hemostasis and Transfusion
    James Bussel; Fiscal Year: 2007

Collaborators

Detail Information

Publications58

  1. ncbi request reprint Novel approaches to refractory immune thrombocytopenic purpura
    J B Bussel
    Department of Pediatrics, Division of Hematology and Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood Rev 16:31-6. 2002
    ..Understanding these cellular immune responses in ITP may lead to the development of more specific immunoregulatory therapies for the management of this disease...
  2. ncbi request reprint AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
    James B Bussel
    New York Presbyterian Hospital, New York, USA
    N Engl J Med 355:1672-81. 2006
    ..Most current treatments for chronic immune thrombocytopenic purpura (ITP) act by decreasing platelet destruction. In a phase 1-2 study, we administered a thrombopoiesis-stimulating protein, AMG 531, to patients with ITP...
  3. ncbi request reprint Novel thrombopoietic agents: preliminary activity, potential benefit
    James B Bussel
    Weill Cornell Medical College, Division of Pediatric Hematology, Payson 609, 525 E 68th Street, New York, NY 10021, USA
    J Support Oncol 5:63-84. 2007
  4. ncbi request reprint Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates
    James B Bussel
    Division of Hematology, Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021 4853, United States
    Blood Rev 22:33-52. 2008
    ..While there have been many advances regarding the diagnosis and treatment of AIT, it is still difficult to predict the severity of disease and which therapy will be effective...
  5. pmc Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration
    James B Bussel
    Departments of Pediatrics and Medicine, Division of Hematology Oncology, Weill Cornell Medical College, New York, NY, USA
    Haematologica 99:1264-71. 2014
    ..The results suggest medical cure may be achievable in immunothrombocytopenia, especially in women and in patients within two years of diagnosis. (clinicaltrials.gov identifier:02050581)...
  6. ncbi request reprint Thrombopoietic agents: There is still much to learn
    James B Bussel
    Weill Cornell Medical College, Platelet Disorders Center, Departments of Pediatrics and Medicine, Division of Hematology, New York, NY 10065, United States Electronic address
    Presse Med 43:e69-78. 2014
    ..Rather than being an "encyclopedic" review, this manuscript is intended to provide a state of the art description of what we do and do not know in regard to important questions about usage of these still novel agents. ..
  7. doi request reprint Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)
    James B Bussel
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Br J Haematol 160:538-46. 2013
    ..If a chronic ITP patient not requiring consistent therapy responds to short-term eltrombopag, then subsequent courses of eltrombopag, as needed, are likely to be safe and effective...
  8. pmc Impact of chronic Immune Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective
    Susan D Mathias
    Health Outcomes Solutions, P, O, Box 2343 Winter Park, Florida 32790, USA
    Health Qual Life Outcomes 6:13. 2008
    ..The aim of this research is to develop a conceptual model to describe the impact of ITP and its treatment on patients' health-related quality of life (HRQoL)...
  9. pmc A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation
    Susan D Mathias
    Ovation Research Group, 188 Embarcadero, San Francisco, CA 94105, USA
    Health Qual Life Outcomes 5:11. 2007
    ..Therefore, we sought to develop and validate the ITP-Patient Assessment Questionnaire (ITP-PAQ) for adult subjects with ITP...
  10. ncbi request reprint Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura
    James B Bussel
    Weill Cornell Medical College of Cornell University, New York, NY 10065, USA
    N Engl J Med 357:2237-47. 2007
    ..The pathogenesis of chronic idiopathic thrombocytopenic purpura (ITP) involves antibody-mediated platelet destruction and reduced platelet production. Stimulation of platelet production may be an effective treatment for this disorder...
  11. ncbi request reprint Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura
    James B Bussel
    Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York 10021 4885, USA
    Am J Hematol 82:192-8. 2007
    ..The results suggest that IGIV-C infused at rates up to 0.14 mL/kg/min in patients with ITP is well tolerated...
  12. ncbi request reprint Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia
    J Bussel
    Platelet Research and Treatment Program, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10065, USA
    J Thromb Haemost 7:253-7. 2009
    ..This creates a risk of in utero ICH even if there was not one in the previous pregnancy. There are new developments in AIT in regard to diagnosis, treatment, and screening which will be the focus of this review...
  13. doi request reprint Current approaches to the evaluation and management of the fetus and neonate with immune thrombocytopenia
    James B Bussel
    Division of Pediatric Hematology Oncology, Weill Cornell Medical College New York Presbyterian Hospital, New York, NY 10065, USA
    Semin Perinatol 33:35-42. 2009
    ..Thus, the accurate diagnosis and appropriate management of this disorder are of extreme importance in perinatal medicine and will constitute the focus of this review...
  14. ncbi request reprint Treatment of immune thrombocytopenic purpura in adults
    James Bussel
    Department of Pediatrics, Division of Hematology and Oncology, and Department of Pediatrics in Medicine and in Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Hematol 43:S3-10; discussion S18-9. 2006
    ..When used as either monotherapy or in combination with conventional therapeutics, these treatments may offer a more tolerable side effect profile and improved clinical benefit compared to existing drugs...
  15. ncbi request reprint Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia
    James B Bussel
    Department of Pediatrics, The New York Hospital, Cornell University Medical Center, New York, New York 10021, USA
    Pediatr Blood Cancer 45:176-83. 2005
    ..This study was undertaken to compare the outcome of cases of AIT to cases of neonatal thrombocytopenia shown not to be AIT and to identify clinical features that would facilitate the diagnosis...
  16. ncbi request reprint Another interaction of the FcR system with IVIG
    James B Bussel
    Division of Pediatrics, Weill Medical College of Cornell University, New York Hospital, New York, NY 10021, USA
    Thromb Haemost 88:890-1. 2002
  17. ncbi request reprint A pilot study of rhuIL-11 treatment of refractory ITP
    J B Bussel
    Weill Medical College of Cornell University New York Presbyterian Hospital, Division of Pediatric Hematology Oncology, New York, New York 10021, USA
    Am J Hematol 66:172-7. 2001
    ..Toxicity was substantial. The lack of platelet response to rhuIL-11 in this study does not exclude the possibility of better effects at other doses and/or in less refractory patients...
  18. ncbi request reprint Traditional and new approaches to the management of immune thrombocytopenia: issues of when and who to treat
    James B Bussel
    Department of Pediatrics, Weill Medical College of Cornell University, 525 E 68th Street, P695, New York, NY 10065, USA
    Hematol Oncol Clin North Am 23:1329-41. 2009
    ..Finally, current studies to augment therapy in newly diagnosed ITP patients to prevent chronic disease may lessen the number of patients in chronic disease category...
  19. ncbi request reprint Therapeutic approaches to secondary immune thrombocytopenic purpura
    James B Bussel
    Platelet Disorders Center, Division of Pediatric Hematology Oncology, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA
    Semin Hematol 46:S44-58. 2009
    ..Unlike primary ITP, treatment often must be tailored to the specific circumstance underlying the secondary ITP, even if the condition itself is incurable...
  20. ncbi request reprint Alloimmune thrombocytopenia in the fetus and newborn
    J B Bussel
    Division of Pediatric Hematology Oncology, New York Presbyterian Hospital Weill Medical College of Cornell University, New York 10021, USA
    Semin Thromb Hemost 27:245-52. 2001
    ..IVIG remains the basis of therapy but appears to require a higher dose (2 g/kg/week) and/or the addition of 1 mg/kg of prednisone in the highest risk cases, those with antenatal intracranial hemorrhage...
  21. doi request reprint A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia
    James B Bussel
    Department of Pediatrics, Division of Hematology, Weill Medical College of Cornell University, New York, NY, USA
    Blood 118:28-36. 2011
    ..In this short-term study, romiplostim increased platelet counts in 88% of children with ITP and was well-tolerated and apparently safe. The trial was registered with http://www.clinicaltrials.gov as NCT00515203...
  22. ncbi request reprint Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy?
    J B Bussel
    Department of Pediatrics, Weill Medical College of Cornell University New York Presbyterian Hospital, New York, New York, USA
    Am J Hematol 67:27-33. 2001
    ..However, a good platelet response in adults to the last IV anti-D and a hemoglobin decrease >/=2.0 gm/dl both appeared to predict response to subsequent splenectomy...
  23. doi request reprint Eltrombopag
    James B Bussel
    Division of Pediatric Hematology Oncology, Department of Pediatrics in Obstetrics and Gynecology and in Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY 10044, USA
    Cancer Treat Res 157:289-303. 2011
    ..We review the first clinical studies with this agent, emphasizing the significant findings...
  24. ncbi request reprint Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus
    James B Bussel
    Department of Pediatrics and Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, NY 10065, USA
    Am J Obstet Gynecol 203:135.e1-14. 2010
    ..We sought to prevent intracranial hemorrhage (ICH) through antenatal management of alloimmune thrombocytopenia...
  25. ncbi request reprint IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life
    James B Bussel
    New York Presbyterian Hospital, Payson 695, 525 East 68th Street, New York, New York 10021 4885, USA
    Thromb Haemost 91:771-8. 2004
    ..Viral safety monitoring for HIV, HCV, HBV and Parvovirus B19 showed no seroconversions on study. In conclusion, IGIV-C is as safe and efficacious as IGIV-S/D in treatment of ITP...
  26. doi request reprint The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia
    Benjamin Levy
    Platelet Research and Treatment Program, Division of Pediatric Hematology Oncology, Weill Cornell Medical College, New York, New York, USA
    Curr Opin Oncol 20:690-6. 2008
    ..This review summarizes the history of the development of thrombopoietic agents and discusses their potential use in chemotherapy-induced thrombocytopenia...
  27. ncbi request reprint Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial
    Richard L Berkowitz
    Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, 622 West 168th Street, New York, NY 10032, USA
    Obstet Gynecol 110:249-55. 2007
    ..The study was limited to "standard-risk" patients, who were defined as women with documented alloimmune thrombocytopenia who had not delivered an infant with an intracranial hemorrhage in a prior pregnancy...
  28. doi request reprint Overview of thrombopoietic agents in the treatment of thrombocytopenia
    Rachel Kobos
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Lymphoma Myeloma 8:33-43. 2008
    ..Development of these agents might also improve the management of diseases such as cancer and hepatitis C, whose current regimens are limited by the occurrence of thrombocytopenia...
  29. ncbi request reprint Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison
    Andromachi Scaradavou
    New York Blood Center, New York, New York, USA
    Am J Hematol 82:335-41. 2007
    ..Anti-D should be the first line therapy in HIV-positive, Rh+ patients, when antiretroviral agents are not indicated, not effective, or there is an urgent need to increase the platelet count...
  30. ncbi request reprint Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP
    James B Bussel
    Department of Pediatrics, Division of Hematology, New York Presbyterian Hospital, NY, USA
    Blood 113:2161-71. 2009
    ..In conclusion, romiplostim increased platelet counts in most patients for up to 156 weeks without tachyphylaxis and had an acceptable safety profile. (ClinicalTrials.gov Identifier NCT00116688)...
  31. ncbi request reprint Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
    James B Bussel
    Weill Cornell Medical College of Cornell University, New York, NY, USA
    Lancet 373:641-8. 2009
    ..This study assessed the efficacy, safety, and tolerability of once daily eltrombopag 50 mg, and explored the efficacy of a dose increase to 75 mg...
  32. pmc Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases
    Bethan Psaila
    Department of Pediatric Hematology Oncology, Weill Cornell Medical Center and NewYork Presbyterian Hospital, New York, NY, USA
    Blood 114:4777-83. 2009
    ..Children with severe thrombocytopenia plus head trauma and/or hematuria appeared to be at particularly high risk of ICH. Aggressive treatment of these children may be appropriate...
  33. ncbi request reprint Alloimmune thrombocytopenia: state of the art 2006
    Richard L Berkowitz
    Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, New York, NY 10032, USA
    Am J Obstet Gynecol 195:907-13. 2006
    ....
  34. pmc Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy
    Kristen M Marks
    Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    J Acquir Immune Defic Syndr 52:595-9. 2009
    ..Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV...
  35. ncbi request reprint Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children
    Mary J Ward
    Department of Pediatrics, Divisions of General Pediatrics and Hematology Oncology, Weill Medical College of Cornell University, New York, New York, USA
    Am J Perinatol 23:487-92. 2006
    ..We speculate that platelets may possibly play a role in neurodevelopmental processes in the fetus...
  36. ncbi request reprint Contemporary treatment of immune thrombocytopenia
    Marina Izak
    1NY Presbyterian Hospital and Weill Cornell Medical College, Division of Pediatric Hematology Oncology, 525 East 68th Street, Payson Pavilion 695, New York, NY 10065, USA
    Expert Rev Hematol 6:697-712. 2013
    ..In this review, focused on adult patients, we discuss newer results of therapies and consider newer treatment strategies...
  37. ncbi request reprint Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment
    Julie Wang
    Department of Pediatrics, Division of Allergy and Immunology, Mount Sinai Medical Center, New York, New York 10029, USA
    J Pediatr 146:217-21. 2005
    ..This study examined the efficacy and safety of rituximab in children with chronic immune thrombocytopenic purpura...
  38. doi request reprint Romiplostim: a second-generation thrombopoietin agonist
    Claudia S Cohn
    Department of Pathology, NY Presbyterian Hospital, New York, NY, USA
    Drugs Today (Barc) 45:175-88. 2009
    ..In addition, antibodies that can stimulate the c-Mpl receptor are being engineered to act as potent TPO agonists. These and other drugs in preclinical development represent a new line of therapy for thrombocytopenic patients...
  39. doi request reprint Maternal and neonatal characteristics associated with neonatal neutropenia in hypertensive pregnancies
    Geeta Sharma
    Department of Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, New York, USA
    Am J Perinatol 26:683-9. 2009
    ..7% versus 2.2% neutropenia in singletons (p < 0.001). Furthermore, multiple gestations with neutropenia had a higher incidence of sepsis than singletons with neutropenia...
  40. doi request reprint Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura
    Ellinor I B Peerschke
    Weill Cornell Medical College of Cornell University, New York, NY, USA
    Br J Haematol 148:638-45. 2010
    ..063). Thus, complement fixation may contribute to the thrombocytopenia of ITP by enhancing clearance of opsonized platelets from the circulation, and/or directly damaging platelets and megakaryocytes...
  41. ncbi request reprint 21. Immunohematologic disorders
    Deepa H Trivedi
    Weill Medical College of Cornell University and New York Presbyterian Hospital, 525 E 67th Street, New York, NY 10031, USA
    J Allergy Clin Immunol 111:S669-76. 2003
    ..Other immune reactions include antibodies to clotting factors, which result in both thrombosis and hemorrhage, and hemolytic and nonhemolytic reactions during transfusion of blood products...
  42. ncbi request reprint Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?
    Nichola Cooper
    Department of Pediatrics, Division of Hematology Oncology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Blood 99:1922-7. 2002
    ..Platelet count at study entry was the primary predictor of outcome...
  43. ncbi request reprint Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy
    Marc Michel
    Department of Pediatrics, Division of Hematology Oncology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Br J Haematol 123:142-6. 2003
    ..The direct antiglobulin test was positive in three out of seven Rh+ newborns, none of whom was anaemic or jaundiced. Anti-D is effective and appears to be safe for both mother and fetus...
  44. ncbi request reprint Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms
    Nichola Cooper
    Division of Hematology Oncology, Department of Pediatrics, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY 10021, USA
    Br J Haematol 124:511-8. 2004
    ....
  45. doi request reprint Refractory immune thrombocytopenic purpura: current strategies for investigation and management
    Bethan Psaila
    Platelet Disorders Center, Division of Pediatric Hematology Oncology, Weill Cornell Medical College of Cornell University, New York, NY 10021, USA
    Br J Haematol 143:16-26. 2008
    ..Morbidity, mortality and heath-related quality of life are also discussed...
  46. ncbi request reprint The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP
    Lemke K Page
    Division of Pediatric Hematology Oncology, Weill Medical College of Cornell University, New York 10021, USA
    Br J Haematol 138:245-8. 2007
    ..The IBLS is a useful clinical tool for monitoring bleeding and may be used to aid the development of laboratory parameters that correlate with underlying bleeding propensity in thrombocytopenia...
  47. pmc Treatment with rituximab in benign and malignant hematologic disorders in children
    Lisa B Giulino
    Weill Medical College of Cornell University, Department of Pediatrics, Division of Hematology Oncology, New York, NY 10021, USA
    J Pediatr 150:338-44, 344.e1. 2007
  48. ncbi request reprint The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
    Nichola Cooper
    Division of Hematology Oncology, Departments of Pediatrics and Medicine, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, NY, USA
    Br J Haematol 125:232-9. 2004
    ..No changes in immunoglobulin levels or infectious complications were seen. In summary, rituximab was well tolerated with no immediate complications and induced a lasting, substantial response in 32% of adults with chronic ITP...
  49. ncbi request reprint Differential diagnosis and management of thrombocytopenia in childhood
    Rosandra N Kaplan
    Weill Medical College of Cornell University, Division of Pediatric Hematology Oncology, New York Presbyterian Hospital Cornell Medical Center, 525 East 68th Street, New York, NY 10021, USA
    Pediatr Clin North Am 51:1109-40, xi. 2004
    ..With each disease process, the pathophysiology as it is currently known is described and discussed...
  50. doi request reprint The effect of anti-CD40 ligand in immune thrombocytopenic purpura
    Vivek L Patel
    Division of Pediatric Hematology Oncology, Weill Medical College of Cornell University, New York, NY, USA
    Br J Haematol 141:545-8. 2008
    ..The 24% (11/46) overall response rate demonstrates the potential role of CD40-CD40L in the pathogenesis of ITP...
  51. pmc Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura
    Jin Yu
    Laboratory of Complement Biology, New York Blood Center, New York, NY 10021, USA
    Blood 112:1325-8. 2008
    ..The impaired suppression was specific to Tregs as shown by cross-mixing experiments with T cells from controls. These data suggest that functional defects in Tregs contribute to breakdown of self-tolerance in patients with chronic ITP...
  52. ncbi request reprint Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)
    Donna M Boruchov
    The Brookdale University Hospital and Medical Center Department of Pediatrics, Hematology Oncology, Brooklyn, NY, USA
    Blood 110:3526-31. 2007
    ..Combination chemotherapy is a useful approach for patients with ITP refractory to conventional treatments both for acute induction and for long-term maintenance therapy...
  53. ncbi request reprint Fetal and neonatal cytopenias: what have we learned?
    James B Bussel
    Department of Pediatrics, Division of Pediatric Hematology Oncology, New York Presbyterian Hospital, New York, New York 10021, USA
    Am J Perinatol 20:425-31. 2003
    ..Antenatal management of affected fetuses with treatment administered to the mother is now well established although studies are ongoing. Neutropenia is a complication of pre-eclampsia; the mechanism is still not well understood...
  54. pmc Fc receptors in immune thrombocytopenias: a target for immunomodulation?
    Bethan Psaila
    Platelet Disorders Center, Division of Pediatric Hematology Oncology, Weill Cornell Medical College of Cornell University, New York, New York 10021, USA
    J Clin Invest 118:2677-81. 2008
    ..These reports illustrate how a remarkably detailed molecular understanding of the FcR network may translate into new therapeutic strategies with high clinical impact...
  55. ncbi request reprint Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?
    Marc Michel
    New York Presbyterian Hospital, Department of Pediatrics, Division of Pediatric Hematology Oncology, Weill Medical College of Cornell University, 525 East 68th St, New York, NY 10021, USA
    Blood 103:890-6. 2004
    ....
  56. ncbi request reprint Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis
    Linda J Butros
    Department of Pediatrics, Columbia Presbyterian Medical Center, New York, New York, USA
    J Pediatr Hematol Oncol 25:660-4. 2003
    ..To ascertain characteristics of children with immune thrombocytopenic purpura (ITP) and intracranial hemorrhage (ICH)...
  57. ncbi request reprint Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease
    Monesha Gupta
    Division of Cardiology, Department of Pediatrics, New York Presbyterian Hospital, New York, N Y, USA
    Cardiology 97:180-2. 2002
    ..Elevation of IgA aCL has been reported in association with other vasculitides and IgA-secreting plasma cells have been demonstrated in the vascular tissue in Kawasaki disease...
  58. doi request reprint Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
    Anna Podolanczuk
    Department of Medicine, New York Presbyterian Hospital, Columbia University Medical Center, New York 10032, USA
    Blood 113:3154-60. 2009
    ..In conclusion, inhibition of Syk was an efficacious means of increasing and maintaining the platelet count in half the patients with chronic refractory ITP. (ClinicalTrials.gov, no. NCT00706342)...

Research Grants1

  1. Novel Therapies in Hemostasis and Transfusion
    James Bussel; Fiscal Year: 2007
    ..Dr. James Bussel, as our site's Primary Investigator, is responsible for ensuring that all aspects of TMH Network protocols are followed. WEILL CORNELL MEDICAL CENTER/NEW YORK PRESBYTERIAN HOSPITAL CRITIQUES ..